AnaptysBio
ANAB
124 hedge funds and large institutions have $633M invested in AnaptysBio in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 39 reducing their positions, and 21 closing their positions.
2,356% more call options, than puts
Call options by funds: $5.03M | Put options by funds: $205K
3.25% more ownership
Funds ownership: 107.31% → 110.55% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 39
5% less funds holding
Funds holding: 131 → 124 (-7)
14% less capital invested
Capital invested by funds: $733M → $633M (-$100M)
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$17.1M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15.5M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$15.2M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$14.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.38M |
Top Sellers
ANAB Hedge Fund Activity: Q2 2022 in Review
124 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2022, worth a combined $633M — down 14% from $733M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ANAB and 18 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 39 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $17.1M. The largest seller was Point72 Asset Management, cutting an estimated $10.3M.
- 124 institutional investors held AnaptysBio (ANAB) as of Q2 2022, down from 131 in Q1 2022.
- Funds reported $633M of AnaptysBio stock for Q2 2022, down 14% quarter-over-quarter.
- 18 funds opened new AnaptysBio positions in Q2 2022 and 21 closed out, a net change of -3 holders.
- The largest AnaptysBio buyer in Q2 2022 was Deerfield Management, an estimated $17.1M added.
- The largest AnaptysBio seller in Q2 2022 was Point72 Asset Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2022.